Clinical Trial Update: Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab and tremelimumab in adults with EGFR-mutant advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: University of Sydney | Conditions: EGFR Mutant Advanced Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN